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Elevated body mass index (BMI) associates with cardiometabolic traits on observational analysis, yet the underlying causal relationships
remain unclear.We conductedMendelian randomization analyses by using a genetic score (GS) comprising 14 BMI-associated SNPs from
a recent discovery analysis to investigate the causal role of BMI in cardiometabolic traits and events. We used eight population-based
cohorts, including 34,538 European-descent individuals (4,407 type 2 diabetes (T2D), 6,073 coronary heart disease (CHD), and 3,813
stroke cases). A 1 kg/m2 genetically elevated BMI increased fasting glucose (0.18 mmol/l; 95% confidence interval (CI) ¼ 0.12–0.24),
fasting insulin (8.5%; 95% CI ¼ 5.9–11.1), interleukin-6 (7.0%; 95% CI ¼ 4.0–10.1), and systolic blood pressure (0.70 mmHg; 95%
CI¼ 0.24–1.16) and reduced high-density lipoprotein cholesterol (0.02mmol/l; 95%CI¼0.03 to0.01) and low-density lipoprotein
cholesterol (LDL-C;0.04 mmol/l; 95%CI¼0.07 to0.01). Observational and causal estimates were directionally concordant, except
for LDL-C. A 1 kg/m2 genetically elevated BMI increased the odds of T2D (odds ratio [OR] ¼ 1.27; 95% CI ¼ 1.18–1.36) but did not alter
risk of CHD (OR 1.01; 95% CI ¼ 0.94–1.08) or stroke (OR ¼ 1.03; 95% CI ¼ 0.95–1.12). A meta-analysis incorporating published studies
reporting 27,465 CHD events in 219,423 individuals yielded a pooled OR of 1.04 (95% CI ¼ 0.97–1.12) per 1 kg/m2 increase in BMI. In
conclusion, we identified causal effects of BMI on several cardiometabolic traits; however, whether BMI causally impacts CHD risk
requires further evidence.Introduction
Over half a billion people worldwide are obese (defined as
a body mass index [BMI] R 30 kg/m2; MIM 601665),1
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has also been shown to play a strong role; heritability esti-
mates range from 40% to 85%.3
Large prospective population studies show that BMI
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glycaemic traits10 (such as fasting glucose [MIM 612108])
and traits that are causally related to CHD, including
blood pressure (MIM 145500) and blood lipids (MIM
604595).9,11,12 However, few randomized trials provide
data that can precisely delineate the underlying causal re-
lationships between BMI and cardiometabolic traits. This
is important because observational associations between
BMI and traits or disease events could arise from confound-
ing (where an association does not reflect a causal relation-
ship) and reverse causality (where the disease process alters
the exposure of interest). Whether BMI causes adverse
levels of traits or risk of outcomes is of critical importance
given that BMI is modifiable. In terms of CHD events, a
recent phase III randomized trial of weight loss for cardio-
vascular-disease prevention was terminated because of a
lack of efficacy.13
An alternative and effective means of investigating
whether an exposure causes an outcome is the use of ge-
netic variants in the Mendelian randomization approach.
This technique exploits the random allocation of genetic
variants at gametogenesis, facilitating their use as instru-
mental variables (traits that can be used as proxies for the
exposure but that are not affected by confounding) for
investigating causality.14 The discrepancy between obser-
vational and randomized evidence to date motivated us
to use a Mendelian randomization approach to investigate
the role of BMI in cardiometabolic traits and events
through instrumental variable analysis.Subjects and Methods
We included up to 34,538 participants from eight cohorts that had
been genotyped with the Human CVD BeadArray (Illumina), also
termed the ‘‘IBC’’ or ‘‘CardioChip’’ array.15
Several studies using this array have been published and have
confirmed previously established associations and identified new
associations between SNPs and several phenotypes and disease
outcomes, including coronary artery disease,16,17 plasma lipids,18
blood pressure,19,20 cardiomyopathy,21 T2D,22 and BMI.23
The eight cohorts used in the current study, listed in Table S1
(available online), are Atherosclerosis Risk in Communities
(ARIC),24 the Cardiovascular Health Study (CHS),25 Coronary
Artery Risk Development in Young Adults (CARDIA),26 the Euro-
pean Prospective Investigation into Cancer and Nutrition
Netherlands (EPIC-NL),27 the Framingham Heart Study (FHS),28
Multinational Etoricoxib and Diclofenac Arthritis Long-term
(MEDAL),29 the Multi-Ethnic Study of Atherosclerosis (MESA),30
and the Women’s Health Initiative (WHI).31
ARIC is a prospective population-based study of atherosclerosis
and cardiovascular diseases in 15,792 men and women, including
11,478 non-Hispanic whites and 4,314 African Americans, drawn
from four United States communities (suburban Minneapolis,
Washington County, Forsyth County, and Jackson). CHS is a pop-
ulation-based longitudinal study of CHD and stroke in adults
aged 65 years and older. The study design called for enrollment
of 1,250 men and women in each of four communities: For-
syth County, Sacramento County, Washington County, and Pitts-
burgh. CARDIA is a prospective, multicenter investigation of theThe Americnatural history and etiology of cardiovascular disease in African
Americans and whites 18–30 years of age at the time of initial ex-
amination. The initial examination included 5,115 participants
selectively recruited to represent proportionate racial, gender,
age, and education groups from four communities: Birmingham,
Chicago, Minneapolis, and Oakland. EPIC-NL is the Dutch contri-
bution to the European Prospective Investigation into Cancer and
Nutrition, recruited between 1993 and 1997, and consists of
the Prospect cohort (a prospective population-based cohort of
17,357 women between 49 and 70 years of age and participating
in breast cancer screening) and the Monitoring Project on Risk
Factors for Chronic Diseases cohort (consisting of 22,654 men
and women between the ages of 20 and 59 years at recruitment
in three Dutch towns, Amsterdam, Maastricht, and Doetinchem).
FHS is a longitudinal observational, community-based cohort
initiated in 1948 in Framingham to prospectively investigate
CVD and its risk factors. The children (and spouses of the chil-
dren) of the original cohort, labeled the Offspring cohort, were
recruited in 1971 and have been examined approximately every
4 years since. The MEDAL program was prospectively designed
to pool data from three randomized, double-blind trials of etori-
coxib versus diclofenac in arthritic individuals between June
2002 and May 2006 across 46 countries: the Etoricoxib versus
Diclofenac Sodium Gastrointestinal Tolerability and Effective-
ness (EDGE) study (ClinicalTrials.gov ID NCT00092703), EDGE
II (ClinicalTrials.gov ID NCT00092742), and the MEDAL study
(ClinicalTrials.gov ID NCT00250445). Recruited subjects were
aged 50 years and older, had a clinical diagnosis of osteoarthritis
(OA) or rheumatoid arthritis (RA), and were adjudged to require
long-term therapy with a nonsteroidal anti-inflammatory drug
or cylo-oxygenase-2 selective inhibitor. In total, 34,701 OA and
RA subjects (7,111 in EDGE, 4,086 in EDGE II, and 23,504 in
the MEDAL study), consisting of 24,913 (72%) OA subjects and
9,787 (28%) RA subjects, were followed for a mean duration of
18 months. The primary endpoint was thrombotic cardiovas-
cular events. MESA is a multicenter prospective cohort study of
the development of subclinical cardiovascular disease. A total of
6,814 women and men between the ages of 45 and 84 years
were recruited for the first examination between 2000 and 2002.
Participants were recruited in six United States cities (Baltimore,
Chicago, Forsyth County, Los Angeles County, Northern Manhat-
tan, and St. Paul).WHI is one of the largest (n¼ 161,808) studies of
women’s health ever undertaken in the United States. There are
two major components of WHI: a clinical trial that enrolled and
randomized 68,132 women aged 50–79 into at least one of three
placebo-control clinical trials (hormone therapy, dietary modifica-
tion, and supplementation with calcium and vitamin D) and an
observational study that enrolled 93,676 women of the same age
range into a parallel prospective cohort study.
We restricted our analysis to individuals of European ancestry to
avoid confounding by population admixture. The investigation
was approved by the institutional review boards of each study,
and written informed consent was obtained from all participants.
ARIC, CHS, CARDIA, FHS, and MESA participated in this project
as part of the NHLBI’s Candidate-Gene Association Resource
Consortium.32
SNP Selection
A recent discovery BMI analysis including over 108,000 indi-
viduals (including cohorts in this analysis) and using the IBC
CardioChip23 facilitated SNP selection for this analysis. All SNPs
that met the array-wide threshold of p < 2.4 3 106 in thean Journal of Human Genetics 94, 198–208, February 6, 2014 199
discovery analysis for BMI were included. Fourteen SNPs were
identified, and their characteristics are listed in Table S2.
Construction of the Genetic Score
To increase precision, weweighted SNPs by the beta coefficients re-
ported in the discovery paper. Because the original discovery paper
presented estimates on the per SD scale,23 we transformed these to
the native units (kg/m2) by multiplying the summary beta coeffi-
cients by the SD of the largest data set reported to date in individ-
uals of European ancestry (1,462,958 individuals; SD ¼ 4.7).4
We then summed the externally weighted value for each SNP in
each individual to create a genetic score (GS). We did not impute
missing genotype (or phenotype) values.
Data Handling
We had access to individual-level data for all participants in the
studies and created a merged data set. We adjusted all analyses
by study and restricted our data set to individuals with nonmissing
data for BMI and the GS. Nonnormally distributed traits were
natural-log transformed (resulting in a Gaussian distribution),
and estimates from the analysis of these transformed traits were
exponentiated and converted to a percent difference in the
geometric mean. For one study with related individuals, only the
eldest person in each family structure was included in the analysis
(Table S1).
Cardiometabolic Traits and Outcomes
We investigated the following cardiometabolic traits and out-
comes: waist circumference (used as a positive control for the BMI
GS), fasting glucose, fasting insulin,C-reactive protein (CRP), inter-
leukin-6 (IL-6), fibrinogen, high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides
(TGs), systolic blood pressure (SBP), diastolic blood pressure (DBP),
carotid intimamedial thickness (cIMT), CHD, stroke, and T2D. The
outcomes (CHD, stroke, and T2D) consisted of combined incident
and prevalent cases and are defined in Table S3.
Genetic Association Analysis
The proportion of variance (R2) and the corresponding 95% confi-
dence interval (CI) of the GS on BMI were estimated in each study,
and values were combined across studies via fixed-effects meta-
analysis. We quantified the first-stage F-statistic to inform on the
strength of the genetic instrument.33 The association between
the GS and cardiometabolic traits and events was estimated by
linear and logistic regression, respectively. We also investigated
the association between the GS and the traditional confounders
age, gender, and smoking status.
Pairwise Correlations between SNPs in BMI GS and
Each Cardiometabolic Trait and Event
We investigated evidence of a genetic dose-response relationship
by plotting pairwise associations of the pooled effect of each SNP
on BMI against the corresponding value for each cardiometa-
bolic trait and event. We tested for evidence of linearity through
metaregression by using the ‘‘metareg’’ command in Stata v.13.1
(StataCorp, College Station).34 ‘‘Metareg’’ conducts a random-
effects meta-regression that is in essence comparable to a linear
regression analysis in which the linear association of BMI
(the independent variable) is tested with each cardiometa-
bolic trait (dependent variable). The analysis is weighted by the
precision of the effect estimates.35 A small p value provides evi-200 The American Journal of Human Genetics 94, 198–208, Februarydence of a linear relationship between BMI and the trait under
investigation.
Instrumental Variable Analysis
To generate the causal estimate per 1 kg/m2 increase in BMI,
we used instrumental variable analyses. For continuous traits, we
used the two-stage least-squares estimator implemented in the
‘‘ivregress’’ command36 in Stata to generate the causal estimate
per 1 kg/m2 increase in BMI, adjusted for study. For binary traits,
we used the logistic control function estimator.37 For this, we first
conducted a linear regression analysis with BMI as the dependent
variable and the GS as the independent variable. We then incorpo-
rated the residuals from the first step into a logistic regression
model of each binary trait on BMI by using robust standard errors,
thereby adjusting for residuals from the first step.
Sensitivity Analyses
We conducted several sensitivity analyses to investigate whether
the estimates obtained from instrumental variable analyses were
influenced by adjustment for traits.
First, we adjusted the instrumental variable analysis for age and
sex. Second, to investigate whether the association between BMI
and LDL-C could be explained by lipid-lowering therapy, we
adjusted for lipid-lowering therapy in the instrumental variable
analysis. Third, to investigate whether the null estimate of BMI
with CHD on instrumental variable analysis could be explained
by the association with LDL-C, we repeated the analysis with
adjustment for LDL-C.
To ensure that bias was not introduced by the combination of in-
cidentandprevalentcases,we investigated incidentcases separately.
Finally, we created a second, stricter GS in which any SNPwithin
a gene that has shown association with a trait unrelated to
adiposity was excluded from the GS. This was based on informa-
tion from the Catalog of Published Genome-Wide Association
Studies.38 The SNPs used in the stricter GS are listed in Table S4.
We tested the association between this stricter GS and the
outcomes—T2D, CHD, and stroke.
Observational Analysis
We conducted minimally adjusted analyses (adjusted for age and
sex) with BMI as the independent variable for each trait of interest
(by using linear and logistic regression for continuous and binary
traits, respectively). This was compared to the estimates derived
from instrumental variable analysis.
Comparison of BMI GS to Findings from the Look
AHEAD: Action for Health in Diabetes Randomized
Trial
The Look AHEAD: Action for Health in Diabetes (Look AHEAD)
trial13,39 was a multicenter trial in which 5,145 overweight partic-
ipants with T2D were randomized to an intensive lifestyle inter-
vention either to lose weight through reduced calorie intake and
increased physical activity (the active arm) or to receive standard
support and education (control arm). The trial ran for a median
of 9.6 years and was terminated for futility when it failed to
show an effect of the intervention on the primary outcome of a
composite of cardiovascular death, nonfatal myocardial infarction
or stroke, or hospitalization for angina.
In order to contextualize the findings from our Mendelian
randomization analysis with that of the Look AHEAD trial, we
scaled the effect of the instrumental variable estimates by the6, 2014
SD per trait
Figure 1. Association between the BMI GS and Cardiometabolic Traits
Effect estimates represent the beta (plotted) or regression (tabulated) coefficients (595% CI) per 1-unit increase in weighted GS. The GS
consisted of 14 SNPs taken from Guo et al.23 For log-transformed variables (marked by an asterisk), the regression coefficients are pre-
sented as a percent difference in the geometric mean.samemagnitude of difference reported in the Look AHEAD trial (in
which the active arm, compared to the control arm, achieved an
average reduction inweightof4kg, equivalent toa1.4kg/m2 reduc-
tion in BMI). Data on all traits and outcomes were obtained from
two publications.13,39 Given that findings for CRP were stratified
by gender and lipid-lowering therapy,39 we combined them
through fixed-effects meta-analysis to achieve an overall percent
difference between intensive lifestyle intervention and usual care.
Comparison of Findings toMendelian Randomization
Studies
To place our findings into the context of previous studies, we
searched PubMed from inception to November 3, 2013, by using
the search term ‘‘(‘‘Mendelian Randomization Analysis’’[Mesh] OR
‘‘Mendelian randomization’’[All Fields] OR ‘‘Mendelian randomiza-
tion’’[All Fields]) AND (‘‘Body Mass Index’’[Mesh] OR ‘‘bmi’’[All
Fields]OR ‘‘bodymass index’’[All Fields]).’’ This retrieved 54 studies,
to which we added one study that was not identified by our search
but that was referenced in a recent publication40 (Figure S1). A total
of seven studies reported traits that overlappedwith those reported
in our analysis. We documented sample size, the number of alleles
used for Mendelian randomization, and the power of the genetic
instruments (measured as the proportion of variance [R2] of BMIThe Americexplained by the genetic instrument or the first-stage F-statistic)
and examined for consistency in the association and direction of
the effect of instrumental variable estimates. In addition, we con-
ducted a meta-analysis of the effect of a 1 kg/m2 increase in BMI
on CHD risk by using fixed- and random-effects modeling imple-
mented in the ‘‘metan’’ command41 in Stata, and we quantified
between-study heterogeneity by using the I2 statistic.42Results
A total of eight cohorts with up to 34,538 individuals were
used in this study (Table S1). The mean age of study partic-
ipants was 60 years (range ¼ 17–100 years), and 65% of
individuals were female. The mean BMI was 27.5 kg/m2
(range ¼ 14.4–69.6 kg/m2). There were 4,407 T2D, 6,073
CHD, and 3,813 stroke cases recorded in the data sets.
The observed allele frequencies for the 14 SNPs
comprising the GS (Table S2) were similar across the eight
cohorts (Figure S2). The weighted GS was normally distrib-
uted in each of the eight studies, and SNPs showed concor-
dant associations with BMI (Figures S3 and S4).an Journal of Human Genetics 94, 198–208, February 6, 2014 201
Figure 2. Association between the BMI GS and Cardiometabolic Events
Effect estimates represent the OR (595% CI) for each outcome per 1-unit increase in weighted GS. The GS consisted of 14 SNPs (taken
from Guo et al.23) that associated with a 1.08 kg/m2 increase in BMI (Figure 1).Association between BMIGS andWaist Circumference
The GS associated with a BMI increase of 1.08 kg/m2 (95%
CI ¼ 0.95–1.21 per unit increase in weighted GS) and ex-
plained 0.8% (95% CI ¼ 0.6%–1.0%) of its variance with
a first-stage F-statistic of 237. We also identified associa-
tions between the GS and waist circumference (2.55 cm;
95% CI ¼ 2.16–2.94), which served as a positive control.Association between BMI GS and Age, Sex, and
Smoking Status
No association between the BMI GS and smoking status
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Figure 3. Observational and Instrumental Variable Estimates of th
Effect estimates represent the beta (plotted) or regression (tabulated)
estimates were adjusted for age, sex, and study. For log-transformed
sented as a percent difference in the geometric mean. Causal estima
202 The American Journal of Human Genetics 94, 198–208, Februaryweighted GS ¼ 1.03; 95% CI ¼ 0.97–1.08) or sex (OR of
male gender ¼ 1.03; 95% CI ¼ 0.97–1.09) was observed.
We identified a weak association between the BMI GS
and reduced age (0.19 years; 95% CI ¼ 0.37 to 0.02).Association between GS and Cardiometabolic Traits
The BMI GS showed strong associations with glycemic,
inflammation, lipid, and blood-pressure traits. For each
unit increase in GS, which associated with a BMI increase
of 1.08 kg/m2, fasting glucose was 0.17 mmol/l (95% CI ¼
0.11–0.22) higher and fasting insulin was 8.4% (95% CI ¼
5.5–11.5) higher. The GS also showed strong associationP (mmHg) 
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tes were derived from instrumental variable (IV) analysis.
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Table 1. Estimates of the Causal Relationship between BMI and
Cardiometabolic Traits and Events
Studies
(Individuals)
Regression Coefficienta
(95% CI)
Metabolic Traits
Fasting glucose
(mmol/l)
6 (20,677) 0.18 (0.12–0.24)
Fasting insulin
(% difference)b
3 (12,758) 8.47 (5.94–11.06)
Inflammation Traits
CRP (% difference)b 7 (24,319) 12.00 (7.95–16.19)
IL-6 (% difference)b 5 (9,885) 7.00 (4.01–10.08)
Fibrinogen
(% difference)b
6 (19,041) 0.92 (0.25–1.59)
Blood-Pressure Traits
SBP (mmHg) 6 (30,136) 0.70 (0.24–1.16)
DBP (mmHg) 6 (30,137) 0.28 (0.03–0.52)
Lipid Traits
HDL-C (mmol/l) 6 (24,943) 0.02 (0.03 to 0.01)
LDL-C (mmol/l) 6 (23,364) 0.04 (0.07 to 0.01)
TGs (% difference)b 6 (24,761) 0.82 (0.61–2.27)
Surrogate Marker of CHD
cIMT (% difference)b 3 (6,260) 1.12 (0.42–2.68)
Events Studies (Cases/
Individuals)
ORa (95% CI)
T2D 7 (4,407/31,844) 1.27 (1.18–1.36)
CHD 7 (6,073/26,193) 1.01 (0.94–1.08)
Stroke 6 (3,813/23,782) 1.03 (0.95–1.12)
These estimates were derived from instrumental variable analysis using the GS
(consistingof14SNPs).Abbreviationsareas follows:CHD,coronaryheartdisease;
CI, confidence interval; cIMT, carotid intima medial thickness; CRP, C-reactive
protein; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein choles-
terol; IL-6, interleukin-6; LDL-C, low-density lipoprotein cholesterol; OR, odds
ratio; SBP, systolic blood pressure; T2D, type 2 diabetes, and TG, triglyceride.
aEstimates are per 1 kg/m2 increase in BMI.
bPercent difference in geometric mean.with CRP (11.8% higher; 95% CI ¼ 7.8–15.9), IL-6 (7.4%
higher; 95% CI ¼ 4.2–10.7), and fibrinogen (0.9% higher;
95% CI ¼ 0.2–1.6). Each unit increase in GS associated
with a reduction in LDL-C and HDL-C of 0.04 mmol/l
(95% CI ¼ 0.06 to 0.01) and 0.016 mmol/l (95% CI ¼
0.030 to 0.005), respectively, and an increase in SBP
and DBP of 0.73 mmHg (95% CI ¼ 0.24–1.21) and
0.29 mmHg (95% CI ¼ 0.02–0.55), respectively (Figure 1).
We identified a significant association between the BMI
GS and T2D risk (OR ¼ 1.29; 95% CI ¼ 1.20–1.39), but
not CHD, stroke, or cIMT (Figures 1 and 2).
Pairwise Associations between SNPs in the GS and
Cardiometabolic Traits and Events
We found strong evidence of a positive genetic dose-
response relationship (meaning that SNPs that associatedThe Americmore strongly with BMI tended to also associate more
strongly with the cardiometabolic trait or outcome) be-
tween BMI SNPs and the following traits: fasting glucose,
fasting insulin, IL-6, and T2D (Figures S5 and S6).
Causal Analysis of BMI on Cardiometabolic Traits
In instrumental variable (causal) analysis, for every
1 kg/m2 increase in BMI, fasting glucose increased by
0.18 mmol/l (95% CI ¼ 0.12–0.24) and fasting insulin
increased by 8.5% (95% CI ¼ 5.9–11.1).
A 1 kg/m2 increase in BMI increased CRP by 12.0% (95%
CI ¼ 8.0–16.2), IL-6 by 7.0% (95% CI ¼ 4.0–10.1), and
fibrinogen by 0.9% (95% CI ¼ 0.3%–1.6%). A 1 kg/m2 in-
crease in BMI increased SBP by 0.70 mmHg (95% CI ¼
0.24–1.16). For these glycemic, inflammatory, and blood-
pressure traits, the instrumental variable estimates were
all directionally concordant and, in general, of similar
magnitude to estimates derived from observational ana-
lyses (Figure 3 and Table 1).
A 1 kg/m2 increase in BMI reduced HDL-C by
0.02 mmol/l (95% CI ¼ 0.03 to 0.01) and LDL-C
by 0.04 mmol/l (95% CI ¼ 0.07 to 0.01). Although
the estimate for HDL-C was concordant with the observa-
tional estimate, the estimate for LDL-C was directionally
opposite.
The point estimates for the instrumental variable esti-
mates for TGs and cIMT were both directionally concor-
dant with observational estimates; however, unlike those
of the observational estimates, the 95% CIs of the instru-
mental variable estimates included the null value (Figure 3
and Table 1).
Causal Analysis of BMI on T2D, CHD, and Stroke
For T2D, a 1 kg/m2 increase in BMI resulted in anORof 1.27
(95% CI ¼ 1.18–1.36), which was similar to (but greater in
magnitude than) the estimate obtained from observational
analysis (OR¼ 1.13; 95%CI¼ 1.12–1.13). We did not iden-
tify evidenceof a causal relationshipbetweenBMIandCHD
(OR¼1.01; 95%CI¼0.94–1.08); however, the95%CIover-
lapped the estimates from observational analysis (OR ¼
1.02; 95% CI ¼ 1.01–1.02; Figure 4). Neither the instru-
mental variable analysis nor the observational analysis
identified an association between BMI and stroke (Table 1).
Similar findings were yielded when CHD and stroke were
restricted to incident-only cases (Table S5).
Sensitivity Analyses
Adjustment of the instrumental variable analysis for age
and gender did not alter any of the estimates (Table S6),
nor did adjustment of the instrumental variable analysis
for CHD events by LDL-C (OR of CHD per 1 kg/m2 increase
in BMI ¼ 1.04; 95% CI ¼ 0.96–1.14) (Table S6). When we
used a stricter GS including SNPs that were more specific
to BMI, the findings of the instrumental variable analysis
for T2D, CHD, and stroke remained unaltered (Table S7).
Whenwe investigated the association between CHD and
the 14 individual SNPs constituting the BMI GS, the SNPsan Journal of Human Genetics 94, 198–208, February 6, 2014 203
Figure 4. Observational and Instrumental Variable Estimates of the Effect of BMI on Cardiometabolic Events
Effect estimates represent the OR (595% CI) per 1 kg/m2 increase in BMI. Observational estimates were adjusted for age, sex, and study.
Causal estimates were derived from instrumental variable (IV) analysis.were evenly balanced around the null estimate (the OR
point estimates were <1, 1, and >1 for six, one, and seven
SNPs, respectively), and not one of the 14 SNPs showed in-
dividual association with CHD (all p values > 0.05). The
heterogeneity between the estimates was low (I2 ¼ 0%),
and the summary estimate derived from the fixed-effects
model was numerically identical to the estimate derived
from the random-effects model in the meta-analysis
(Figure S7). This was in contrast to the association between
the individual SNPs and T2D, for which the majority of
SNPs (11 of 14) had a point estimate concordant with a
positive association and five showed individual association
at p < 0.05.Comparison of Findings from the GS to the Look
AHEAD Trial
When we compared findings from the recently published
Look AHEAD trial to a comparable difference in BMI by
using the GS, the estimates from both the GS and the trial
were concordant for all traits (Table 2).Comparison of Findings to Published Studies
We identified seven previous Mendelian randomization
studies that investigated BMI and cardiometabolic events
(Figure S1).40,43–48 Consistent with the findings we report,
all prior Mendelian randomization studies identified
causal effects of BMI on levels of fasting insulin, CRP,204 The American Journal of Human Genetics 94, 198–208, FebruarySBP, DBP, and risk of T2D. In contrast, there was a discrep-
ancy for fasting glucose, IL-6, LDL-C, TGs, cIMT, and CHD
(Table S8).
For CHD, we conducted a meta-analysis of instrumental
variable estimates from three studies (including this
report) with a total of 27,465 CHD events in 219,423 indi-
viduals. This yielded a pooled OR estimate of 1.05 (95%
CI ¼ 1.00–1.10) for fixed-effects models and 1.04 (95%
CI ¼ 0.97–1.12) for random-effects models and moderate
between-study heterogeneity (I2 ¼ 50%) (Figure 5).Discussion
We used a Mendelian randomization approach to investi-
gate the causal role of BMI on a wide range of cardiometa-
bolic traits. Our analysis, which combined 14 BMI SNPs
in order to maximize power,49 supports the importance
of BMI in regulating cardiometabolic traits and T2D
risk, but the precise causal relationship between BMI and
CHD and stroke is less clear.
The general similarity between the estimates obtained
from causal (instrumental variable) analysis and those
from a minimally adjusted observational analysis for the
continuous cardiometabolic traits is striking and indicates
that there is little unmeasured confounding in the obser-
vational estimates (i.e., our findings suggest that the
observed relationships of BMI are very close to the causal6, 2014
Table 2. Randomized Evidence of a Causal Relationship between BMI and Cardiometabolic Traits and Events from Genetic and Trial Data
Mendelian Randomization Estimate Using GS
(14 SNPs) in Healthy Individuals (per 1.4 kg/m2
Reduction in BMI)
Look AHEAD Trial in Overweight or Obese
Individuals with T2D (Intensive Lifestyle
Intervention versus Diabetes Support and
Education)a
Cardiometabolic
Traits Individuals
Mean Difference
(95% CI) p Value Individualsb
Mean Difference
(95% CI) p Value Concordant
SBP (mmHg) 30,136 1.01 (1.67 to 0.34) 0.003 5,145 1.9 (2.6 to 1.1) <0.05 yes
DBP (mmHg) 30,137 0.39 (0.75 to 0.04) 0.03 5,145 0.1 (0.5–0.3) 0.72 yesc
LDL-C (mmol/l)d 23,364 0.05 (0.01–0.09) 0.01 5,145 0.04 (0.01–0.08) <0.05 yes
HDL-C (mmol/l)d 24,943 0.02 (0.01–0.04) 0.004 5,145 0.03 (0.02–0.05) <0.05 yes
TGs (% difference) 24,761 1.16 (3.15–0.87) 0.26 5,145 1 (4–1) 0.26 yes
CRP (% difference) 24,319 14.96 (19.32 to 10.36) 1.6 3 109 5,145 30.1 (52.4 to 7.7) 0.008 yes
Cardiometabolic
Events
Events/
Individuals
OR (95% CI) p Value Events/
Individuals
OR (95% CI) p Value
CHD 6,073/26,193 0.99 (0.90–1.09) 0.79 354/5,145 0.84 (0.68–1.04) 0.11 yes
Stroke 3,813/23,782 0.95 (0.85–1.07) 0.42 165/5,145 1.05 (0.77–1.42) 0.78 yes
Abbreviations are as follows: CHD, coronary heart disease; CI, confidence interval; CRP, C-reactive protein; DBP, diastolic blood pressure; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; SBP, systolic blood pressure; T2D, type 2 diabetes, and TG, triglyceride.
aCompared to the control arm (randomized to diabetes support and education), the intervention arm (randomized to intensive lifestyle intervention) in the
Look AHEAD trial experienced a BMI reduction of 1.4 kg/m2. In order to provide a comparable estimate, we estimated the Mendelian randomization instrumental
variable for the same magnitude of difference of BMI.
bThe precise numbers of individuals contributing to each trait are not reported.
cAlthough the estimate from the Look AHEAD trial was not statistically significant for DBP, the direction of effect was consistent with that obtained from the
Mendelian randomization analysis.
dLDL-C and HDL-C were converted from mg/dl to mmol/l by multiplication by 0.02586.estimates rather than arising from bias or confounding).
Our findings suggest that reductions in BMI are likely to
result in reduced blood pressure, inflammation, fasting
glucose and insulin, and risk of T2D and therefore improve
the cardiometabolicmilieu. Furthermore, our instrumental
variable estimates provide a direct quantification of the
effect of a 1 kg/m2 alteration in BMI on these cardiometa-
bolic traits. These findings are an important enhancement
to previous Mendelian randomization studies and ran-
domized trials that have evaluated the effect of lifestyle
intervention on risk of T2D.50,51
When we compared the estimates from the instru-
mental variable analysis to observational (nongenetic)
estimates for clinical events, which can be affected by
bias or confounding, we found concordant estimates for
T2D risk and stroke; however, this was not the case for
CHD. No single SNP in the GS showed association with
CHD, and the heterogeneity between the SNPs was low.
Therefore, the null association with CHD was a general
characteristic shared by all SNPs in the BMI GS. That
said, the observational estimate of the effect of BMI on
risk of CHD was of small magnitude (OR ¼ 1.02; 95%
CI ¼ 1.01–1.03 per 1 kg/m2 increase in BMI), and the
95% CI overlapped the estimate from instrumental vari-
able analysis, meaning that we might have had insuffi-
cient power to identify a small effect of BMI on CHD if
it were present.
In support of our data is the concordance between our
Mendelian randomized estimates for all traits (includingThe AmericCHD) and the clinical-trial randomized estimates from
the Look AHEAD trial.13 Combining the Mendelian
randomization estimates from published studies with our
own gave a total sample size of 219,423 individuals,
including 27,465 CHD events, and yielded an estimate
that is inconclusive (the OR for a 1 kg/m2 increase in
BMI on risk of CHD was 1.04; 95% CI ¼ 0.97–1.12 with
considerable between-study heterogeneity). This high-
lights the need for further large studies using randomized
evidence to resolve this important question.
BMI is a complex phenotype, and SNPs that associate
with subphenotypes of BMI could potentially have impor-
tant roles in CHD; this requires further investigation using
SNPs specific to refined adiposity phenotypes. Studies
included in this analysis contributed to the original dis-
covery analysis,23 and thus use of overlapping studies for
discovery and Mendelian randomization analysis could
theoretically result in model overfitting. Our instrumental
variable (causal) analysis made the assumption of a linear
relationship14 between BMI and cardiometabolic traits
and events. This is at odds with some published observa-
tional studies.4 Specifically, observational studies have
suggested that individuals with low BMI might have a
higher mortality rate than individuals with normal BMI,
creating an apparent J-shaped curve. However, debate per-
sists as to whether this J-shaped association reflects a true
protective effect of moderate BMI (compared to low BMI)
or whether it is an artifact arising from concurrent illness
in some individuals in the low-BMI group and thusan Journal of Human Genetics 94, 198–208, February 6, 2014 205
Fixed-effects summary estimate (I2 = 50%)
Study
 Random-effects summary estimate
Fall et al.40
Nordestgaard et al.48
Current paper
SNPs
1
3
14
Cases/Total
10,372/109,258
11,056/75,627
6,037/34,538
1.046 (0.998, 1.096)
OR per 1 kg/m2 
Increase in BMI (95% CI)
1.043 (0.973, 1.119)
0.995 (0.879, 1.126)
1.110 (1.029, 1.197)
1.010 (0.940, 1.080)
10.8 1.2
OR
Figure 5. Meta-analysis of Studies Investigating the Effect of BMI on CHD through Mendelian Randomization Analysis
Effect estimates represent the OR (595% CI) per 1 kg/m2 increase in BMI on the odds of CHD.appears as a protective effect of normal BMI (a form of
reverse causality).52
Additional assumptions of Mendelian randomization14
are (1) that the GS associates with the exposure of interest
(in this case, BMI, which we provide very strong evidence
for), (2) that the GS only associates with the outcomes
through BMI, and (3) that the GS is not influenced by con-
founding factors. In this regard, the use of multiple SNPs in
the GS should in theory enhance specificity of the GS for
BMI (reducing the possibility that the GS has pleiotropic
effects, i.e., effects nonspecific to BMI). It remains theoreti-
cally plausible that a subset of SNPs in the GS also affect
glycemic traits (independently of BMI), which could poten-
tially violate the instrumental variable assumptions. Against
this is the general concordance between our findings and
those of previous Mendelian randomization studies using
different genetic variants (Table S8) and the Look AHEAD
trial (Table 2). Confounding should be minimized from the
randomized inheritance of the alleles used for generating
the GS. A further advantage of using multiple SNPs in a GS
for Mendelian randomization analysis is that it can increase
statistical power by explaining a greater proportion of
variance of BMI. Despite this, only a small proportion
(0.8%) of the variance of BMI was explained. However, the
proportion of variance of drugs on their target phenotypes
is also small; for example, blood-pressure-lowering drugs
explain only a small proportion of the variance of SBP
(~2% in our data set), yet there is indisputable evidence of
the causal role of SBP in CHD from phase III randomized
controlled trials.53 Finally, Mendelian randomization miti-
gates the bias that can arise from nondifferential measure-
ment error in BMI.54
In conclusion, our findings quantify the causal rela-
tionships between BMI and cardiometabolic traits and206 The American Journal of Human Genetics 94, 198–208, Februaryoutcomes. With the use of a GS derived from 14 SNPs
for Mendelian randomization, an increase in BMI re-
sulted in increased fasting glucose and insulin, SBP,
inflammation, and risk of T2D. However, we did not
identify a causal effect between BMI and CHD. Whether
a reduction in BMI impacts risk of CHD events requires
further evidence from appropriately designed randomized
studies.Supplemental Data
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